30 closest matches · ranked by relevance
HER2-ve Metastatic Breast Cancer · Germline BRCA1/2 Mutations · Somatic BRCA1/2 Mutations
Primary: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants — 8.18 months
Ovarian Carcinoma · Breast Cancer
Primary: Objective Response Rate (ORR) Evaluated According to Response Evaluation Criteria In Solid Tumors (RECIST) Guidelines — 75; 30.77; 0; 25.58 Percentage of participants
Ovarian Cancer · Breast Cancer
Primary: Haematology: Basophils Absolute Count, Eosinophils Absolute Count, Leucocytes WBC, Lymphocytes Absolute Count, Monocytes Absolute Count, Neutrophils Absolute Count, and…
Breast Cancer
Primary: Test Uptake: Number of Clients Who Indicated Intention to Have Genetic Testing — 14; 15; 2; 0 Participants
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 12.6; 14.6 months — p=0.003
HER2-negative Breast Cancer
Primary: Objective Response Rate (ORR) as Assessed by Independent Radiology Review (IRC) — 38.2; 61.9 Percentage of participants — p=0.0210
Breast Cancer · Metastatic Breast Cancer · BRCA1 Gene Mutation
Primary: Objective Response Rate (ORR) of ABT-888 and Temozolomide (TMZ) in Metastatic Breast Cancer — 4; 3 Participants
Advanced Breast Cancer · HER2/Neu Negative · Triple-Negative Breast Cancer
Primary: Objective Response (OR) — 0; 0; 0; 3 Participants
Breast Cancer
Primary: Overall Response Rate (ORR) Per RECIST1.1 — 7 Participants
Prostate Cancer
Primary: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers — 0 participants
Breast Cancer
Primary: Overall Response Rate (ORR) — 40.7; 5.0; 8.8 percentage
Ovarian · Breast · Prostate
Primary: Tumour Response Rate — 12.9; 31.1; 21.7; 50 Percentage of participants
Breast Cancer · Ovarian Insufficiency · Ovarian Failure
Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants
Breast Cancer
Primary: Disease-free Survival — 5.44; 5.45 DFS events/100*person-year
Ovarian Cancer
Primary: Number of Survivors Using Website Access Code — 147; 202 Participants
Metastatic Breast Cancer · Breast Neoplasms
Primary: Time to Treatment Failure (TTF) for Talazoparib — 5.5 Months
Breast Cancer Metastatic · BRCA 1 Gene Mutation · BRCA 2 Gene Mutation
Primary: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) — 7.0…
Advanced Ovarian Cancer · Primary Peritoneal Cancer · Advanced Breast Cancer
Primary: Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy — 44.4…
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Primary: Objective Response Rate (ORR) — 109; 37 Count of Participants — p=0.002
Germline BRCA1/2 Mutations and · Metastatic Adenocarcinoma of the Pancreas
Primary: Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified…
Breast Cancer
Primary: Rate of Genetic Counseling and Testing Uptake. — 18; 15; 7; 12 Participants
Breast Cancer · Ovarian Cancer
Primary: Objective Response Rate to 6-mercaptopurine and Methotrexate (6MP/MTX) in This Patient Population. — 22 Participants
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Primary: Objective Response Rate, Defined as the Percentage of Subjects With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) — 69.3; 64.0…
BRCA or HRR+ Mutated Ovarian Cancer Patients
Primary: Progression-Free Survival (PFS) — 18.0; 16.6 months
Hereditary Cancer · Mental Health Issue
Primary: Connor Davidson Resilience Scale (CDRISC) — 22.59; 23.53 score on a scale — p=.029
Genetic Predisposition
Primary: Rates of Screening — 9892; 3813 Participants — p=0.0074
Breast Cancer
Primary: Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ…
Non-Germline BRCA Mutated Ovarian Cancer
Primary: Progression Free Survival (PFS) — 9.2 months
Breast Cancer
Primary: Change in Proliferation of Breast Epithelial Cells Obtained by Random Periareolar Fine Needle Aspiration. — -2.3 Change in % of cells positive for Ki-67
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Primary: Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD Regimen — 0; 1; 0 Participants